PTCT stock PTC therapeutics Inc com
SHAREHOLDER ALERT: POMERANTZ LAW FIRM INVESTIGATES CLAIMS ON BEHALF OF INVESTORS OF PTC THERAPEUTICS, INC.
Shares of PTC Therapeutics (PTCT) have plunged more than 31% in Tuesday's pre-market session after it received a Refuse to File letter from the U.S. Food and Drug Administration (FDA) regarding the company's New Drug Application (NDA) for Translarna to treat muscular dystrophy.
Chart
Result
No comments:
Post a Comment